Coherus BioSciences, Inc., a global biosimilar company, is currently advancing three late-stage clinical products towards commercialization, namely CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar).
In October, we reported that the FDA accepted Coherus’s aBLA for their pegfilgrastim biosimilar CHS-1701. Today, Coherus announced the acceptance of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for CHS-1701. This marks their first submission and acceptance in Europe.
Stay tuned to Big Molecule Watch for updates on this story and more.